File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1111/cen.15010
- Scopus: eid_2-s2.0-85180506020
- PMID: 38127469
- WOS: WOS:001129465800001
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Serum thrombospondin-2 level changes with liver stiffness improvement in patients with type 2 diabetes
Title | Serum thrombospondin-2 level changes with liver stiffness improvement in patients with type 2 diabetes |
---|---|
Authors | |
Keywords | DPP4 inhibitor FIB-4 NFS SGLT2 inhibitor |
Issue Date | 21-Dec-2023 |
Publisher | Wiley |
Citation | Clinical Endocrinology, 2023 How to Cite? |
Abstract | Objective: Baseline circulating thrombospondin-2 (TSP2) level was identified as a potential novel hepatic fibrosis biomarker that associates with development and progression of hepatic fibrosis in patients with nonalcoholic fatty liver disease and type 2 diabetes. Here, we investigated whether circulating TSP2 levels changed with improvement in liver stiffness (LS), which reflects liver fibrosis on transient elastography. Design: Serum TSP2 levels were measured in participants from a randomized, open-label intervention study, at baseline and after 24-weeks treatment of either dapagliflozin 10 mg (N = 30) or sitagliptin 100 mg daily (N = 30). Vibration-controlled transient elastography was performed to evaluate the severity of hepatic fibrosis and steatosis using LS and controlled attenuation parameter (CAP), respectively. Patients and measurements: Among all 60 participants with similar clinical characteristics at baseline (mean HbA1c 8.9%, CAP 289 dB/m and LS 5.8 kPa), despite similar HbA1c lowering, treatment with dapagliflozin, but not sitagliptin, led to significant improvements in body weight (BW) (p = .012), CAP (p = .015) and LS (p = .011) after 24 weeks. Results: Serum TSP2 level decreased significantly from baseline in dapagliflozin-treated participants (p = .035), whereas no significant change was observed with sitagliptin. In correlation analysis, change in serum TSP2 levels only positively correlated with change in LS (r = .487, p = .006), but not with changes in BW, CAP or HbA1c after dapagliflozin treatment. Conclusions: Serum TSP2 level decreased with LS after dapagliflozin treatment, and was independent of improvements in BW, glycemic control and hepatic steatosis, further supporting the potential of serum TSP2 level as a novel hepatic fibrosis biomarker in type 2 diabetes. |
Persistent Identifier | http://hdl.handle.net/10722/339705 |
ISSN | 2023 Impact Factor: 3.0 2023 SCImago Journal Rankings: 0.978 |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Mak, Jimmy Ho Cheung | - |
dc.contributor.author | Lui, David Tak-Wai | - |
dc.contributor.author | Fong, Carol Ho-Yi | - |
dc.contributor.author | Cheung, Chloe Yu-Yan | - |
dc.contributor.author | Wong, Ying | - |
dc.contributor.author | Lee, Alan Chun-Hong | - |
dc.contributor.author | Hoo, Ruby Lai-Chong | - |
dc.contributor.author | Xu, Aimin | - |
dc.contributor.author | Tan, Kathryn Choon-Beng | - |
dc.contributor.author | Lam, Karen Siu-Ling | - |
dc.contributor.author | Lee, Chi-Ho | - |
dc.date.accessioned | 2024-03-11T10:38:43Z | - |
dc.date.available | 2024-03-11T10:38:43Z | - |
dc.date.issued | 2023-12-21 | - |
dc.identifier.citation | Clinical Endocrinology, 2023 | - |
dc.identifier.issn | 0300-0664 | - |
dc.identifier.uri | http://hdl.handle.net/10722/339705 | - |
dc.description.abstract | <p><strong>Objective: </strong>Baseline circulating thrombospondin-2 (TSP2) level was identified as a potential novel hepatic fibrosis biomarker that associates with development and progression of hepatic fibrosis in patients with nonalcoholic fatty liver disease and type 2 diabetes. Here, we investigated whether circulating TSP2 levels changed with improvement in liver stiffness (LS), which reflects liver fibrosis on transient elastography.</p><p><strong>Design: </strong>Serum TSP2 levels were measured in participants from a randomized, open-label intervention study, at baseline and after 24-weeks treatment of either dapagliflozin 10 mg (N = 30) or sitagliptin 100 mg daily (N = 30). Vibration-controlled transient elastography was performed to evaluate the severity of hepatic fibrosis and steatosis using LS and controlled attenuation parameter (CAP), respectively.</p><p><strong>Patients and measurements: </strong>Among all 60 participants with similar clinical characteristics at baseline (mean HbA1c 8.9%, CAP 289 dB/m and LS 5.8 kPa), despite similar HbA1c lowering, treatment with dapagliflozin, but not sitagliptin, led to significant improvements in body weight (BW) (p = .012), CAP (p = .015) and LS (p = .011) after 24 weeks.</p><p><strong>Results: </strong>Serum TSP2 level decreased significantly from baseline in dapagliflozin-treated participants (p = .035), whereas no significant change was observed with sitagliptin. In correlation analysis, change in serum TSP2 levels only positively correlated with change in LS (r = .487, p = .006), but not with changes in BW, CAP or HbA1c after dapagliflozin treatment.</p><p><strong>Conclusions: </strong>Serum TSP2 level decreased with LS after dapagliflozin treatment, and was independent of improvements in BW, glycemic control and hepatic steatosis, further supporting the potential of serum TSP2 level as a novel hepatic fibrosis biomarker in type 2 diabetes.</p> | - |
dc.language | eng | - |
dc.publisher | Wiley | - |
dc.relation.ispartof | Clinical Endocrinology | - |
dc.rights | This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. | - |
dc.subject | DPP4 inhibitor | - |
dc.subject | FIB-4 | - |
dc.subject | NFS | - |
dc.subject | SGLT2 inhibitor | - |
dc.title | Serum thrombospondin-2 level changes with liver stiffness improvement in patients with type 2 diabetes | - |
dc.type | Article | - |
dc.identifier.doi | 10.1111/cen.15010 | - |
dc.identifier.pmid | 38127469 | - |
dc.identifier.scopus | eid_2-s2.0-85180506020 | - |
dc.identifier.eissn | 1365-2265 | - |
dc.identifier.isi | WOS:001129465800001 | - |
dc.identifier.issnl | 0300-0664 | - |